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ABSTRACT: The highly cytotoxic diruthenium complex 
[(p-MeC6H4Pr
i)2Ru2(SC6H4-p-Me)3]
+ (1), water-soluble 
as the chloride salt, is shown to eﬃciently catalyze oxidation 
of the thiols cysteine and glutathione to give the correspond-
ing disulﬁdes, which may explain its high in vitro anticancer 
activity.
Organometallic complexes oﬀer aspects for medicinal chem-istry that are not available with organic drugs, in particular
because of their coordination and redox properties.1 For this
reason, metal-based pharmaceuticals have found a steadily in-
creasing interest ever since the discovery of the anticancer activity
of cis-Pt(NH3)2Cl2 (cisplatin).
2 The quest for alternative anti-
cancer drugs, particularly stimulated by the serious side eﬀects of
platinum-based cancer therapies,3 resulted in a variety of cyto-
toxic organometallics, of which areneruthenium complexes oc-
cupy a prominent position because of their unique combination
of lipophilic and hydrophilic properties.4
Themode of action by which areneruthenium complexes exert
their antitumoral or antimetastatic eﬀects is not yet fully under-
stood. By analogy with platinum complexes, it was originally
expected that DNA binding was also the main reason for the
anticancer activity of ruthenium complexes, but serum proteins
have also been discussed as possible targets.5 While the ability of
ruthenium to bind to DNA has been demonstrated,6 in particular
for areneruthenium ethylenediamine complexes,7 it was ob-
served that DNA binding of ruthenium was weaker and diﬀerent
from that observed for platinum.8 These ﬁndings suggest diﬀer-
ent modes of action depending on the type of complexes. Thus,
the RAPTA-type areneruthenium complexes (Chart S1 in the
Supporting Information, SI), originally designed to improve the
aqueous solubility,9 have been found to target thioredoxin
reductase and cathepsin B, proteins that act as enzymes in the
cells.10
Another mode of action has been found for areneruthenium
iodoazopyridine complexes, which are surprisingly cytotoxic
despite their inertness to ligand substitution: In a pioneering
study, Sadler and co-workers demonstrated these complexes to
act as catalysts for oxidation of the tripeptide glutathione,
supposed to be at the origin of their anticancer activity.11
In this paper, we report the p-cymene p-toluenethiolato
derivative [(p-CH3C6H4Pr
i)2Ru2(SC6H4-p-CH3)3]
+ (1; Chart 1 )
of the dinuclear complex family [(arene)2Ru2(SR)3]
+,12 which
we had found to be highly cytotoxic for human ovarian cancer
cells (with IC50 values in the nanomolar range for both the cell
line A2780 and cisplatin-resistant line A2780 CisR),13 to act as an
eﬃcient catalyst for oxidation of the thiols cysteine (Cys) and
glutathione (GSH).
Complex 1 has been synthesized as previously described12 and
characterized by standard spectroscopic methods. The stability
of 1 was assessed by recording 1H NMR spectra over 24 h at
37 C. The spectra show (Figure S1 in the SI) that 1 is absolutely
stable in D2O, dimethyl sulfoxide (DMSO)-d6, D2O/DMSO-d6
(95:5), with or without the addition of 100 mM NaCl (close to
extracellular [Cl]).
The interactions between 1 and glucose, all amino acids, and
nucleotides were monitored by NMR spectroscopy, and, surpris-
ingly, only Cys and GSH induced changes in the 1H and 13C
NMR spectra compared to the free components. Figure 1 shows
the 1H NMR spectra obtained upon titration of Cys into a
solution of 1 in D2O with 50 mM NaCl. In agreement with the
1H NMR spectrum of free Cys, the addition of 1 equiv of Cys
resulted in the appearance of newCys resonances atδ 4.17 (Hα),
3.46 (Hβ0), and 3.27 (Hβ). These new 1H signals increased over
time, relative to the signals of free Cys, and, in agreement with the
literature, were assigned as arising from cystine.14
The addition of 1 equiv of GSH resulted in the appearance of
new Cys resonances at δ 4.78 (Hα), 3.33 (Hβ0), and 3.04 (Hβ)
(Figure 2). As for Cys, these new signals increased over time,
relative to the signals of free GSH, and, in agreement with the
literature, were assigned as arising from oxidized glutathione
(GSSG).15
Interestingly, titrations with Cys and GSH revealed that only
the 1H and 13C chemical shifts of the α-CH and β-CH2 groups of
Cys were aﬀected, whereas the chemical shifts of the complex and
the other amino acids remained unperturbed (Figures 2 and 3
and S2 in the SI). These results strongly suggest that Cys and
GSH do not form stable adducts with 1, which was further
evidenced by DOSY spectra (Figure S3 in the SI). From these 1H
NMR titration experiments, it became apparent that 1 can act as a
very eﬃcient catalyst for oxidation of Cys to cystine and of GSH
to GSSG:
RSH þ RSH sf1 RSSR þ H2 ð1Þ
In order to evaluate the catalytic performance of 1, we
followed the 1H NMR spectra of mixtures of 1 with Cys and
GSH with the ratio 1:100, respectively, over time. The catalytic
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conversion of GSH to GSSG may be directly related to the
anticancer activity. Cancer cells are known to have a higher GSH
pool than healthy cells, and in all living cells, more than 90% of
the total GSH pool is in the reduced form (GSH) and less than
10% exists in the disulﬁde form (GSSG). An increased GSSG-to-
GSH ratio is considered to be indicative of oxidative stress, which
damages all components of the cell, including proteins, lipids,
and DNA and which may lead to apoptosis.16 For Cys, the 1H
NMR spectra showed that the reaction led to a steady oxidation
of Cys to cystine after only 14 h, which led to a turnover
frequency after 50% conversion (TOF50) of 8.1 h
1 (Figure 3).
We point out here that the catalytic reaction of complex 1 could
also be performed using a ratio of 1:1000. The reaction led to a
TOF50 of 80.9 h
1 (Figure S5 in the SI). Steady oxidation was
evidenced by the complete disappearance of the original reso-
nances of Cys at δ 4.03 (Hα), 3.17 (Hβ0), and 3.09 (Hβ)
(Figure 2). The formation of cystine during the reaction was
further conﬁrmed by electrospray ionization mass spectrometry
(ESI-MS) spectra (Figure S6 in the SI).
For GSH, the 1H NMR spectra revealed steady oxidation of
GSH to GSSG after 16 h (Figure 3), with TOF50 being 7.4 h
1
(Table 1). Steady oxidation was also evidenced by the complete
disappearance of the original resonances of Cys in GSH at δ 4.61
(Hα), 3.02 (Hβ0), and 2.96 (Hβ) (Figure 2). Formation of
GSSG during the reaction was further conﬁrmed by ESI-MS
spectra (Figure S7 in the SI). It is worth pointing out that, for an
identical complex/GSH ratio (1:100), TOF50 obtained for
complex 1 is about 1 order of magnitude higher than TOF
obtained for iodo-containing ruthenium(II) arene organometal-
lic derivatives (0.37 h1).11 In addition, incubation of 10 mM
GSH with these complexes led to steady oxidation of only
4.6 mM GSH to GSSG, whereas oxidation is complete for
complex 1. Moreover, complex 1 is stable during the reactions
and can be recovered unchanged as the chloride salt, as shown by
1HNMR spectra of the reaction of 1with Cys and GSH recorded
at t = 0 and 24 h (Figures S8 and S9 in the SI). To test the stability
of the catalyst, 100 equiv of Cys was oxidized, and the reaction
was reiterated ﬁve times using the same catalyst (Figure S10 in
Chart 1. Complex 1a
aThe counteranion is Cl.
Figure 1. 1H NMR spectra of Cys (top), 1 (middle), and a mixture of 1
andCys (ratio 1:1, bottom) recorded at 37 C inD2O/DMSO-d6 (95:5)
after 2 h of incubation. The resonances of Cys are indicated by * and the
resonances of cystine by +. The residual water signal is visible around
4.7 ppm.
Figure 2. 1H NMR spectra of GSH (top), 1 (middle), and a mixture of
1 and GSH (ratio 1:1, bottom) recorded at 37 C in D2O/DMSO-d6
(95:5) after 2 h of incubation. The resonances of Cys (GSH) are
indicated by * and the resonances of cystine (GSSG) by +. The residual
water signal is visible around 4.7 ppm.
Figure 3. Turnover number (TON) for mixtures of 1/Cys (2) and
1/GSH (b) (ratio 1:100) in D2O at 37 C with 50 mM NaCl under
argon and 1/Cys (4) and 1/GSH (O) under the same reaction
conditions as those above but under O2.
Table 1. TOFs after 50% Conversion (TOF50) for Oxidation
of Cys to Cystine and of GSH to GSSG with 1 as a Catalyst
(the Values Are Given per Ruthenium Atom)
TOF50/h
1 at 37 C
pD = 4, 50 mM
NaCl
pD = 7, 50 mM
NaCl
pD = 10, 50 mM
NaCl
pD = 7, 4 mM
NaCl
Cys 8.1 8.1 7.2 6.5
GSH 7 7.4 6.9 6
2
the SI). The stability of 1 is remarkable, and TOF50 drops by only
15% after the ﬁfth run.
The results for oxidation of Cys to cystine and of GSH to
GSSG as a function of the pH and [Cl] are shown in Table 1. It
can be seen that TOF50 slightly decreases under basic condi-
tions, whereas acidic conditions have no inﬂuence. The higher
TOF50 values observed for 1 under acidic conditions open new
avenues for further modiﬁcations with the requirement that
future complexes exhibit eﬃcient oxidation only under acidic
conditions. Examples of complexes that undergo hydrolysis/
activation only in cancer cells have recently been reported.17
Likewise, the diﬀerence between [Cl] in blood plasma and in
the cytoplasm has been recently exploited for the design of
ruthenium complexes that should only be activated or hydro-
lyzed once inside the cancer cells.7b However, Table 1 shows
that TOF50 drops by about 20% in concert with decreasing
[Cl] from 50 to 4 mM. Further modiﬁcations of 1 will be
required, aiming at higher TOF50 values for increasing chloride
concentrations.
In the present study, we have shown that the dinuclear
areneruthenium trithiolato complex 1 is inert toward biological
model compounds and yet highly cytotoxic toward A2780 cancer
cell lines. Supramolecular enzyme inhibition, although unlikely,
cannot be completely ruled out. In line with areneruthenium
iodoazopyridine complexes,11 obviously, 1 has a diﬀerent me-
chanism of cancer cell cytotoxicity, involving highly eﬃcient
catalytic oxidation of the major intracellular reducing agent GSH
to GSSG. This complex might have the advantage of not being
poisoned as metal catalysts and therefore might have greater
potential for biological activity. Unlike the large majority of
ruthenium complexes considered so far, complex 1 was found to
be about 2 times more cytotoxic against the A2780 CisR cell
line.13 Interestingly, the intracellular GSH content was shown to
be much higher in A2780 CisR cells.18 Therefore, the highly
eﬃcient catalytic oxidation of GSH to GSSG might explain the
better cytotoxicity of 1 against the cisplatin-resistant line A2780
CisR. Further studies to compare the cytotoxicity and catalytic
activity with the nature of the bridging thiophenolato ligands and
for ﬁne-tuning of the inﬂuence of the pH and [Cl] on TOF50
are under investigation.
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